Navigating the Evolving Paradigm in Heart Failure: The Emerging Impact of SGLT2 Inhibition

October 1, 2020

This educational initiative is targeted to physicians, nurses, nurse practitioners, pharmacists, scientists, and health care professionals who specialize or have an interest in heart failure. Designed to provide an exhaustive overview of new and emerging data as well as foster meaningful collaboration, this accredited activity will evaluate the pathophysiologic mechanisms linking type 2 diabetes (T2D) and heart failure (HF), and explore the early evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs). Expert faculty will then examine new and emerging CVOT data for SGLT2 inhibitors in HFrEF and HFpEF, including recent approvals and updated guideline recommendations, and offer insights into how these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients. To reinforce these teaching points within the context of an integrated treatment approach, attendees will be engaged in a case-based discussion focused on the implementation of SGLT2 inhibitors in HF patients predicated on evolving CVOT data, in tandem with identification of key characteristics of an effective, integrated approach to HF management.


This educational activity is presented by Creative Educational Concepts.

 

 

Registration for the 24th Annual Scientific Meeting is required to attend this symposium.

 

 

Accredited Sponsor: Heart Failure Society of America​​​​​​

 

 

 

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.


This activity is supported by an independent educational grant from AstraZeneca.  

Target Audience

Physicians, nurse practitioners, pharmacists, scientists, and health care professionals who specialize or have an interest in heart failure.

Learning Objectives

Following this activity, participants will be able to:

  1. Review the link between type 2 diabetes (T2D) and heart failure (HF), exploring how this knowledge has impacted evaluation of heart failure outcomes in contemporary CVOT trials. 
  2. Analyze the latest CVOT data for SGLT2 inhibitors, exploring the impact of these agents on diabetic and nondiabetic patients. 
  3. Appraise SGLT2 inhibitor trial data in HFrEF and HFpEF, including their established utility in HF prevention and their prospective role in HF treatment. 
  4. Using a case-based approach, design treatment strategies for patients with heart failure focusing on when and how to appropriately initiate SGLT2 inhibitors.
Course summary
Course opens: 
09/08/2020
Course expires: 
10/01/2020
Event starts: 
10/01/2020 - 4:30pm
Event ends: 
10/01/2020 - 5:45pm
Rating: 
0

4:30 PM-4:35 PM        
Welcome and Introductions/Pre-test
Javed Butler, MD, MPH, MBA (Activity Chair)

4:35 PM-4:50 PM    
A Review of Cardiovascular Outcomes Trial (CVOT) Data: Exploring the Pivotal Link Between T2D and HF 
Suzanne V. Arnold, MD, MHA

4:50 PM-5:15 PM    
Stepping Beyond the Status Quo: How SGLT2 Inhibitors are Bridging the Chasm in Heart Failure  
Javed Butler, MD, MPH, MBA and John McMurray, MD

5:15 PM-5:35 PM     
Revolutionizing Heart Failure Outcomes: Meeting Complex Clinical Challenges through Strategic Collaboration
Muthiah Vaduganathan, MD, MPH    

5:35 PM-5:45 PM        
Conversations with the Experts/Audience Q&A/Post-test 
All Faculty, moderated by Javed Butler, MD, MPH, MBA 

 

Accredited Sponsor: Heart Failure Society of America

 Javed Butler, MD, MPH, MBA 
 Professor and Chairman, Department of Medicine
 University of Mississippi
 Jackson, MS
 

Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson Mississippi. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.

He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.

Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.

 

Suzanne V. Arnold, MD, MHA
Associate Professor of Medicine, Cardiovascular Disease
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City
Kansas City, Missouri

Dr. Suzanne Arnold was born in Ohio and attended undergraduate school and medical school at The Ohio State University in Columbus, Ohio. She completed a residency in Internal Medicine and a fellowship in Cardiovascular Diseases at Washington University in St. Louis. She is board certified in Internal Medicine, Cardiology, and Echocardiography. She also completed a research fellowship through the American Heart Association in cardiovascular outcomes research. She joined Saint Luke's Health System in 2012, and her primary clinical interests are in geriatric cardiology and valvular heart disease. She is actively involved in multiple research projects studying the long-term outcomes of patients with aortic stenosis and patients with chronic coronary disease. She was the recipient of several research awards, including the Burton Sobel Award for Excellence in Cardiovascular Research at Washington University in St. Louis and the American Heart Association Young Investigator Award.

 

 John McMurray, MD
 Professor of Medical Cardiology and Deputy Director  (Clinical) 
 Institute of Cardiovascular and Medical Sciences 
 Queen Elizabeth University Hospital
 University of Glasgow 
 Glasgow, UK

Professor McMurray is currently Professor of Medical Cardiology and Deputy Director (Clinical) of the Institute of Cardiovascular and Medical Sciences and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.

Professor McMurray’s primary research interests are in heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials.  He is, or was, the principal investigator, member of the executive committee or steering committee member for several large trials in his areas of interest including CHARM-Added, EMPHASIS-HF, PARADIGM-HF, Harmony-Outcomes, PARAGON-HF, DAPA-HF and DAPA-CKD.

Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at the Brigham and Women’s Hospital, Boston, and visiting Professor of Medicine, Harvard University, Boston, Massachusetts USA 2010/2011. He is a Past-President of the Heart Failure Association of the ESC. He is a Highly Cited Researcher and he has been involved in many guideline committees, including chairing the Task Force for 2011/2012 ESC Guidelines on heart failure. Professor McMurray is also an associate editor/member of the editorial board of several journals including the European Heart Journal and New England Journal of Medicine.

He has won several awards, including the Stokes Medal of the Irish Cardiac Society. In June 2015, Professor John McMurray and Professor Salim Yusuf (McMaster University, Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases). Prof McMurray is the recipient of the Mackenzie Medal, which is awarded by the British Cardiovascular Society in recognition of outstanding service to British Cardiology. He is also the recipient of the Louis and Artur Lucian Award for Research in Circulatory Diseases, which is awarded each year by McGill University, Montreal. This international award recognizes outstanding research in the field of circulatory diseases by a scientific investigator, or group of investigators, whose contribution to knowledge in this field is deemed worthy of special recognition. Professor McMurray was awarded an OBE in 2019 by Her Majesty the Queen, in recognition of his services to cardiovascular research. In 2020 he was awarded the Gold Medal of the European Society of Cardiology, which the society describes as “the highest honour it can bestow on exceptional scientists for their contribution to cardiovascular medicine”.
 

 Muthiah Vaduganathan, MD, MPH
 Harvard Medical School
 Brigham and Women’s Hospital
 Cardiovascular Medicine
 Boston, Massachusetts


Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA) He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications. 

Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media / CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.

 

Accredited Sponsor: Heart Failure Society of America

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
 
The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™.  Learners should claim only the credit commensurate with the extent of their participation in the activity.  

 

Accredited Sponsor: Heart Failure Society of America

Please login or register to take this course.